Expression of E3 Ubiquitin Ligases in Multiple Myeloma Patients after Treatment with the Proteasome Inhibitor Bortezomib

Expression of E3 Ubiquitin Ligases in Multiple Myeloma Patients after Treatment with the Proteasome Inhibitor Bortezomib

Aim: Clinical success of the proteasome inhibitor bortezomib for multiple myeloma (MM) treatment highlights the potential of therapeutically targeting the ubiquitin (Ub) + proteasome system. However, bortezomib treatment invariably leads to therapeutic resistance through mechanisms that remain elusi...

Full description

Bibliographic Details
Main Author: James Joseph Driscoll
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2015-01-01
Series:Cancer Translational Medicine
Subjects:
Bortezomib
drug resistance
E3 ubiquitin ligase
multiple myeloma
proteasome
Online Access:http://www.cancertm.com/article.asp?issn=2395-3977;year=2015;volume=1;issue=5;spage=153;epage=157;aulast=Driscoll

Internet

http://www.cancertm.com/article.asp?issn=2395-3977;year=2015;volume=1;issue=5;spage=153;epage=157;aulast=Driscoll

Similar Items